Live Review | Ms. Yuan Shaoxiong, Deputy General Manager of Leadingpharm’s Clinical Business Unit, Elaborates on “End‑to‑End” Clinical Development Strategy and Discusses Future Trends

Recently, Ms. Yuan Shaoxiong, Deputy General Manager and Medical Commercial Director of the Clinical Business Unit at Beijing Leadingpharm Pharmaceutical Technology Development Co., Ltd., was invited by the “Clinical Research People” platform to deliver a live lecture on the theme “End‑to‑End Clinical Development Design under the New Landscape.”
 

Drawing on over a decade of hands‑on industry experience, combined with the company’s practical case studies and the latest industry research findings, Ms. Yuan systematically deconstructed the core logic and implementation pathways of “end‑to‑end” clinical development design, and discussed future trends and challenges. The lecture provided a thorough and in‑depth professional sharing for pharmaceutical R&D practitioners, eliciting active interactions and widespread industry attention and positive feedback.
 

Speaker Profile: Deep Expertise in Clinical Development, Strategic Leadership
 

Ms. Yuan Shaoxiong, as a core management talent in Leadingpharm’s Clinical Business Unit, oversees the company’s clinical development strategy and execution, directly managing the three core departments of Medical Affairs, Commercial, and Biostatistics. With over ten years of in‑depth experience in innovative drug R&D, she has accumulated extensive practical expertise in clinical trial protocol design, cross‑functional project management, and drug registration, and is consistently dedicated to advancing China’s innovative drug development.
 

Live Playback – Scan the QR code to watch the replay.

 

Core Sharing: Multi‑Dimensional Analysis Unlocks Clinical Development Code
 

As the pharmaceutical R&D environment evolves and regulatory requirements become increasingly stringent, traditional clinical development models face numerous challenges. End‑to‑end clinical development design, as an innovative strategy, requires us to define the final market target and patient needs from the very beginning of drug development, optimize trial design and resource allocation, and thereby improve R&D efficiency and success rates.
 

Flexible protocol design is a critical tool for achieving clinical development goals. In terms of therapy selection, innovative modalities such as bispecific antibodies, CPIs, TCEs, and CAR‑T have shown remarkable efficacy—for example, CD19 and BCMA dual‑target CAR‑T can cover all stages of B‑cell‑related diseases. In trial design, adaptive designs such as BOIN, i3+3, group sequential design, and sample size re‑estimation allow for dynamic adjustments based on trial progress. Meanwhile, different technology platforms like ADC, PDC, and ACC each have their own advantages and can be flexibly selected according to targeting, efficacy, and safety requirements.

 

Classic cases provide rich practical insights for clinical development. In oncology, bispecific antibodies act through dual‑pathway signal blockade and immune checkpoint mechanisms—e.g., Amivantamab targeting EGFR×c‑Met for NSCLC. Quantitative pharmacology applications include deriving pediatric doses from adult data and optimizing dosing regimens through exposure‑biomarker‑efficacy relationships. In gene therapy, breakthroughs in exon skipping and gene replacement for DMD offer new options for rare diseases.
 

Artificial intelligence is driving comprehensive innovation in clinical development. In data management, AI uses NLP to convert unstructured data, automates data cleaning, quality control, and analysis, and synthetic data technology overcomes privacy constraints. During trial execution, AI can optimize protocol design, intelligently match and recruit patients, improve adherence via chatbots and wearables, and optimize site resource allocation.
 

Cross‑disciplinary collaboration and continuous innovation are vital pillars for clinical development success. In early‑stage development, quantitative pharmacology, medical, and statistical teams work together to determine starting doses and trial plans, while regulatory affairs engage early to ensure design meets registration requirements. In the pivotal development and submission phases, medical and statistical teams define endpoints and analysis methods, quantitative pharmacology aids dose selection and special population identification, and regulatory affairs leads the integration of data to form a complete “product story.”
 

In summary, the end‑to‑end strategy runs through the entire clinical development process, playing a central role in improving R&D efficiency, focusing on patient needs, and addressing regulatory challenges. In the future, deeper integration of AI and real‑world data will drive a paradigm shift toward data‑driven R&D; regulatory science will continue to innovate to match the complexity and internationalization of new drug development; and patient engagement will shift from passive participation to active co‑creation. The industry needs to build a lifecycle‑wide “end‑start loop,” strengthen cross‑functional collaboration and end‑goal orientation, and continuously innovate while ensuring compliance, so as to maximize clinical and market value.
 

Beijing Leadingpharm is always committed to advancing progress in the innovative drug clinical industry through professional clinical development strategy and execution capabilities. This live broadcast was an important initiative for the company to share industry experience and build a professional exchange platform. In the future, Leadingpharm will continue to focus on industry hotspots and cutting‑edge technologies, deliver more professional sharing and industry collaboration, disseminate advanced R&D concepts and practical methods, and join hands with pharmaceutical R&D practitioners to solve development challenges and help China’s pharmaceutical industry reach new heights.
 

- END -